Perspectives on stem cell therapy for cardiac regeneration. Advances and challenges.
Ischemic heart disease (IHD) accelerates cardiomyocyte loss, but the developing stem cell research could be useful for regenerating a variety of tissue cells, including cardiomyocytes. Diverse sources of stem cells for IHD have been reported, including embryonic stem cells, induced pluripotent stem cells, skeletal myoblasts, bone marrow-derived stem cells, mesenchymal stem cells, and cardiac stem cells. However, stem cells have unique advantages and disadvantages for cardiac tissue regeneration, which are important considerations in determining the specific cells for improving cell survival and long-term engraftment after transplantation. Additionally, the dosage and administration method of stem cells need to be standardized to increase stability and efficacy for clinical applications. Accordingly, this review presents a summary of the stem cell therapies that have been studied for cardiac regeneration thus far, and discusses the direction of future cardiac regeneration research for stem cells.
Laboratory of Cardiovascular Regeneration, Division of Cardiovascular Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea School of Medicine, Seoul, South Korea.
Sung Hyun
SH
Choi
Seok Yun
SY
Jung
Sang-Mo
SM
Kwon
Sang Hong
SH
Baek
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002454:Cell Differentiation; D049109:Cell Proliferation; D002470:Cell Survival; D006331:Heart Diseases / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D032383:Myocytes, Cardiac / Q000378:metabolism / Q000473:pathology / Q000637:transplantation*; D020127:Recovery of Function; D012038:Regeneration; D033581:Stem Cell Transplantation / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers